Background: Peptide-derived drugs represent an emerging class of prohibited substances in professional sports and, thus, in modern doping controls. After parental administration (e.g. subcutaneous, intravenous), these drugs undergo various metabolic processes, which degrade them to biologically active or inactive peptides. Knowledge about these metabolic processes and the hereby produced metabolites plays a key role in successful doping controls due to the effective design of analytical assays under consideration of optimal analytical targets. Unfortunately, the complexity of biological matrix (e.g. blood or urine) complicates the immediate identification of relevant metabolites due to the enormous excess of naturally occurring peptides and their degradation products. Methods: In this study, a strategy employing in-vitro metabolism of stable isotope-labeled peptides producing characteristic reporter ions derived from labeled immonium ions is shown. The in-vitro experiments were performed with human skin tissue microsomes (S9), and model drugs representing prohibited peptide hormones were synacthen, insulin, and corticorelin (respectively, their stable isotope-labeled analogs). After generic sample preparation, the metabolites were identified by means of liquid chromatography (LC) coupled to high-resolution mass spectrometry (MS) in an untargeted approach. Results and conclusions: For all three model peptides, several metabolic products were readily identified. While insulin and corticorelin were found to be comparably stable, synacthen was fully degraded, yielding a plethora of metabolic products. A proof of concept concerning the transferability of the obtained data was accomplished by analyzing plasma samples collected post-administration of recombinant human insulin, corroborating the presence of a skin protease-indicative insulin metabolite in vivo.
Introduction
Studying the metabolism of peptide hormones is vital and critical for efficient doping controls or related analytical fields, especially in the light of the plethora of emerging peptide-derived drug candidates, numerous of which possess the potential for misuse in sports [1, 2] . Furthermore, peptide-based drugs will play also a major role in clinical chemistry due to a steadily increasing number of approved drugs [3] . Recent data show that approximately 10% of the entire pharmaceutical market is composed of peptide/protein-based drugs and the proportion soars; thus, the relevancy for therapeutic drug monitoring or other clinical relevant fields will grow accordingly [4] . At the same time, these substances and their yet unknown metabolic fate represent a major analytical challenge as appropriate in-vitro models have been difficult to create and the identification of degradation products from complex peptide-and protein-containing matrices has been particularly time-consuming [5] . The analysis of these peptide hormones in doping controls largely consider the analysis of the intact amino acid sequence only and several assays have been published in this regard recently [6] [7] [8] [9] . Also, the investigation of peptide metabolism by means of mass spectrometry (MS) represents a common approach in this field [10] . Established in-vitro metabolism strategies using human liver microsomal preparations (as commonly applied in studies with lowmolecular-mass drugs) do not allow for generating a comprehensive and representative profile of metabolites in the case of proteins or larger peptides [11] [12] [13] [14] . However, detailed information about metabolic products and, thus, potential target analytes is crucial for meaningful modern sports drug testing programs. Such metabolites are largely unknown for most of the peptides currently considered as prohibited in sports, for example, the insulin-like growth factor-I and its analogs, synacthen, tesamorelin, growth hormone, and others. These peptide and protein-based drugs are therapeutically applied by parenteral routes (subcutaneous [s.c.] or intravenous [i.v.] injection), and especially s.c.-administered drugs are therefore subjected to various proteases present in the subcutaneous tissue before entering the circulation [15] .
In this context, it was recently shown that metabolites produced by these processes provide crucial information for the surreptitious administration of recombinant human insulin in doping controls [15] [16] [17] [18] . Hence, in-vitro models utilizing skin tissue microsomes were found to support adequately simulating conditions of parenteral drug administrations, and the formation of relevant metabolites that de facto occur in vivo was reported [19] . These microsomes were produced as sub-cellular fraction from (human) skin tissue by (S9)-fractionation. Besides the inherent important endo-resp. exoproteinase enzyme activity, which is important to produce the relevant peptide metabolites, also hydrolase and glucuronidation activity is reported [5, 15, 19] . In principle, these microsomes were applied for an in-vitro experiment as already established for classical S9 fractions from other tissues (hepatic cells, etc.) [5] . The reliable and comprehensive identification of metabolic products derived from the peptidic drugs is the second essential step in expanding the analytical options of doping control laboratories. Due to the enormous variety of molecular masses of peptides and proteins of interest, their metabolites can vary substantially from the administered compound and, thus, complicate their identification from biological matrices [2] . A new approach referred to as stable isotope-labeled reporter ion screening (IRIS) utilizing peptides and proteins comprising stable isotopelabeled amino acids has shown great promise in facilitating metabolite identification studies (vide infra). Similar but yet clearly different from metabolite identification strategies employing isotope ratio MS [20] , the monitoring of reporter (immonium) ions of non-natural (isotopically labeled) composition has been shown to enable the detection of compounds unequivocally resulting from induced metabolism and/or degradation processes of the drug (candidate). In this study, this feature of commonly appearing immonium ions generated by internal dissociation of single amino acids from the peptide backbone as "flags" for metabolites was exploited. In combination with in-vitro metabolism incubations of stable isotopelabeled peptides and proteins, the metabolism of peptides of particular relevance for doping controls was revisited to complement the array of measurands supporting the identification of drug cheats in sports.
Materials and methods

Chemicals and reagents
Water, acetonitrile, and formic acid (all ultrapure for nano-liquid chromatography) were purchased from Biosolve (Valkenswaard, The Netherlands). Acetic acid (glacial), acetonitrile (analytical grade), sodium dihydrogenphosphate dihydrate (p.a.), disodium hydrogenphosphate dodecahydrate (p.a.), and sodium chloride (p.a.) were purchased from Merck (Darmstadt, Germany). Tris(carboxyethyl) phosphine hydrochloride (TCEP-HCl) and phosphate-buffered saline tablets were from Sigma (Schnelldorf, Germany). Recombinant human insulin was supplied by Aventis (Kansas City, MO, USA). Solid-phase extraction cartridges OASIS MCX (30 mg, 3 mL) were bought from Waters (Eschborn, Germany). All aqueous buffers and solutions were prepared in Milli-Q water. Recombinant human insulin was from Aventis (Frankfurt, Germany). The labeled insulin standard [[ 2 H 10 ] Leu B6,B11,B15,B17 ]-Insulin (human) was purchased from PeptaNova (Sandhausen, Germany). Synacthen Depot 1 mg was from Novartis Pharma (Bern, Switzerland). [ 2 H 8 ]-valine-labeled synacthen was a custom synthesis from BMFZ (Düsseldorf, Germany). Corticotropin (CRH) and the 13 C 6 -leucine-labeled corticotropin was purchased from Bachem (Switzerland). Human skin tissue microsomes were from Xenotech (Lenexa, MO, USA).
In-vitro experiments
All target peptides (labeled and unlabeled insulin, synacthen and corticotropin) were incubated with human microsomes (and S9 fraction), mimicking the conditions of an s.c. injection. In detail, 1 μg of all peptides was dissolved in 100 μL of PBS and 10 μL of human skin S9 fraction suspension (containing 4 mg of protein/mL in 50 mM Tris, 150 mM KCl, and 2 mM EDTA) and incubated for 2 h at 37 °C with gentle shaking. Afterward, the sample solution was fortified with 200 μL of acetonitrile and the precipitated proteins were separated by centrifugation. The supernatant was concentrated in a vacuum centrifuge and the residue of approximately 10 μL was reconstituted with 90 μL of aqueous acetic acid (2%). After another centrifugation, the samples were ready for injection into the liquid chromatography-MS (LC-MS) system. In all series of incubation experiments, enzyme blank (without skin fraction) and substrate blank (without target peptide) samples were prepared to allow for differentiating metabolic from incubation artefact reactions. Further, all experiments were performed with the labeled as well as the unlabeled model peptides in order to ensure the applicability of the results to authentic samples.
Liquid chromatography
Separation of the target analytes was conducted by means of liquid chromatograph (Thermo Vanquish, Bremen, Germany) using a C-8 analytical column (Poroshell, 3 × 50 mm, Agilent, Karlsruhe, Germany) and a flow rate of 350 μL/min. Water with formic acid (0.1%) and acetonitrile (containing 1% of DMSO and 0.1% of formic acid) were used as solvents A and B, respectively, for gradient elution. The gradient started at 99% A and decreased to 40% of A within 14 min. After a short (1 min) cleaning step at 90% of B, the system was re-equilibrated for 3 min at starting conditions. The resulting overall runtime was 18 min and the injection volume was 10 μL.
Mass spectrometry
A Q Exactive HF-X high-resolution mass spectrometer (Thermo, Bremen, Germany) was used for the detection of the target peptides. The instrument was operated in the positive ionization mode acquiring data in the full-scan mode (m/z 400-1500, resolution 60,000 FWHM) and all-ion fragmentation (AIF, m/z 80-800, resolution 30,000 FWHM). For identification of the in-vitro generated metabolites, AIF experiments were monitored for the generated reporter ions. Subsequently, the full MS data were screened for the respective intact masses of the metabolites. Targeted tandem MS experiments were finally performed for amino acid sequence information and identification of the metabolites. The instrument was calibrated according to the manufacturer's recommendations using a calibration mixture (consisting of caffeine, the tetrapeptide MRFA, and Ultramark). The gas supply consisted of nitrogen (N 2 -generator, CMC, Eschborn, Germany). Ionization in the positive mode was accomplished at a voltage of 3.5 kV and the temperature of the transfer capillary was adjusted to 550 °C. The main characteristics of the target analytes are summarized in Table 1 .
Sample preparation with mixed-mode cation exchange
An ice-cold mixture of 600 μL of acetonitrile/methanol (1:1) is added to 250 μL of serum (or plasma) in an Eppendorf tube. After vortex, the tube is centrifuged for 10 min at 17,000 × g and the supernatant is transferred to a new 2-mL Eppendorf tube. To this tube, 1.4 mL of acetic acid (1%) is added and the volume is vortexed. Solid-phase extraction is performed with mixed-mode cation-exchange cartridges (Waters MCX, 3 cm 3 , 30 mg), which are pre-conditioned with 1 mL of methanol and 1 mL of water prior to loading the sample solution from the 2-mL Eppendorf tube. The samples are washed with 2 mL of water and 2 mL of methanol (acidified with 2% of acetic acid). Finally, the retained analytes are eluted into a new 1.5-mL Eppendorf tube with a mixture of methanol/ammonium hydroxide solution (5:1) and the volume is reduced to approximately 10 μL in a vacuum centrifuge. The residue is topped up with 80 μL of acetic acid (1%), and 20 μL of the resulting mixture is injected into the LC-MS system.
Results and discussion
In-vitro metabolism experiments
In order to effectively simulate metabolic reactions and degradation processes of peptide-based drugs in vitro, the use of skin tissue microsomes was recently suggested and reported [16, 17, 19] . It is noteworthy that, in these early studies, the availability of skin tissue microsomes was limited to animal sources (e.g. rat skin), but the present investigation utilized human skin microsomes that became commercially available. In this study, generic (non-optimized) incubation times and conditions for the metabolism with microsomes were applied. Changes in these conditions will certainly alter the metabolism pattern and a time and/or temperature-dependent metabolism profile will produce other metabolites potentially. Further, in contrast to previous works, the extraction of the generated metabolites was performed by means of non-specific (not antibody-based) sample clean-up with protein precipitation and/or mixed-mode solidphase extraction only. Herewith, in the present study, all occurring metabolites were considered regardless of any retained affinity binding capability to antibodies. 
Insulin
The first model peptide used to test the herein employed approach was stable isotope-labeled insulin, which was utilized as an internal standard in earlier studies [21] . Figures 1 and 2 illustrate the stable IRIS concept for this prohibited peptide drug, comprising four 2 H 10 -labeled leucine residues in the B-chain. The immonium reporter ion exhibits the diagnostic mass shift from m/z 86.10 to 96.16 accordingly ( Figure 1A) . In Figure 1B , the mass spectrum of the unlabeled insulin is shown for comparison.
The natural occurrence of such a labeled immonium ion can be excluded and the extraction of the ion trace at m/z 96.16 from the AIF is accordingly very diagnostic. Of note, the mass spectrum (see Figure 1A) of the labeled insulin additionally shows the unlabeled immonium ion at m/z 86.16 originating from leucine/isoleucine residues from the A-chain. The extracted ion chromatogram (measured in the AIF mode), presenting the reporter ion at m/z 96.16, yields several additional peaks for in-vitro generated metabolites ( Figure 2) , and amino acid sequences were tentatively assigned as supported by the analytes' accurate intact mass. Insulin demonstrates a substantial resistance toward skin-derived proteases, and thus, the intact drug was obtained as the most abundant signal after incubation (see signal at 8.3 min). Nevertheless, four metabolites were identified, assigned to DesB 30 -human insulin, human insulin B-chain, DesB 23−30 human insulin, and partly reduced human insulin (see also Figure S1 ). Additionally, to a lesser extent, also fragments of the B-chain were identified (B 23−30 , B 26−30 , and B 27−30 ). Under the chosen chromatographic conditions, the main metabolite DesB 30human insulin was not fully separated from the intact drug, but the respective full MS mass spectrum corroborates its presence. It is noteworthy that potential metabolites deriving from the cleaved A-chain cannot be detected with this approach as the A-chain of the herein employed isotope-labeled insulin lacks deuterated amino acid residues ( Figure 1 ). However, as most of the synthetic insulin analogs bear modifications at the B-chain, metabolites from the A-chain would not provide the required diagnostic specificity.
Synacthen
Peptidic drugs are frequently analyzed in routine doping controls by targeting the intact drug and, in the absence of verified metabolic products, also for the prohibited substance synacthen, the unmodified therapeutic is preferably determined in routine doping controls [22, 23] . Using the herein presented approach, the labeled analog of synacthen was metabolized in vitro and degradation products were monitored. As shown in Figure 3 , the stable isotope-labeled synacthen comprises three valine residues, which were eight-fold deuterium labeled for the purpose of this study. As a result, an abundant reporter ion at m/z 80.13 is generated, originating from the immonium ion of valine presenting at m/z 72.08 when analyzing the non-deuterated version.
Extracting this reporter ion with high mass accuracy from the full MS chromatogram after incubation of deuterated synacthen with skin tissue microsomes, a substantial number of metabolic products of synacthen are observed (Figure 4) . At least eight different degradation products of synacthen were identified, while the intact synacthen was not detected following a 2-h incubation period. In contrast, the enzyme blank specimen did contain significant amounts of intact synacthen under identical conditions, confirming the proteolysis caused by the microsomal preparation (data not shown). Repeating the experiment with unlabeled synacthen yielded the same (unlabeled) metabolites and provided the relevant characteristics (exact mass, retention time, charge state) of the target peptides for incorporation into routine doping control analysis. In Figure 5 , the product ion mass spectrum of the main metabolite of (unlabeled) synacthen (Syn 1-15) is depicted, obtained from the three-fold protonated precursor ion at m/z 603.63. 
Corticotropin
The third model peptide of this study was corticotropin, 13 C 6 -labeled at the leucine located at position 10 [24] . Consequently, the immonium ion of leucine is expected to shift from m/z 86.1 to m/z 91.1, representing the reporter ion for labeled leucine-containing degradation products. After incubation with skin microsomes, the extracted ion chromatogram produced from AIF experiments and yielding the reporter ion at m/z 91.1 was evaluated for potentially formed metabolites of corticotropin. The obtained data suggest that corticotropin features a considerable stability against enzymatic degradation under the chosen conditions, and only a few minor metabolites were generated. After 2 h of incubation, the intact CRH represented the most abundant signal in the chromatogram with an intense signal at 10.5 min for the four-fold protonated precursor of intact corticotropin ( Figure 6 and Figure S2 ). Evaluating the corresponding enzyme blank chromatogram confirmed that the observed metabolism was the result of the skin microsome addition and not caused by the incubation (exposure to temperature) alone. It is noteworthy that the incorporation of a single labeled amino acid (Leu 10 ) into a peptide as large as 5 kDa appears to limit the detection efficacy of reporter ions and might contribute to a suboptimal analytical result. Consequently, the introduction of a greater number of labeled amino acid residues, preferably distributed more evenly over the peptide of interest (e.g. accomplished in the case of synacthen), is recommended to enhance the signal intensities for the reporter ions of interest. In the case of CRH, labeled analogs (with a higher number of labeled amino acids) were not commercially available, and thus, we decided to apply the approach even under those sub-optimal conditions. Herewith, additionally, the limitations and shortcomings of the presented approach were characterized. Nevertheless, five C-terminally truncated metabolites (CRH 1-19, CRH 1-35, CRH 1-37, CHR 1-38, and CRH 1-39) were detected from the in-vitro incubation experiments. Figure 6 shows the extracted ion chromatograms of the labeled CRH after incubation with skin tissue microsomes compared to the incubation without microsomes (enzyme blank). The enzyme blank results do not feature signals of metabolites but the intact drug only. Here, screening for the intact drug in doping control samples appears advisable, representing the best analytical option according to this data as pursued in a recent assay [24] .
Summary of metabolism studies
Altogether, 19 different metabolic products of the three model peptides were identified employing the combination of skin tissue microsome-based in-vitro metabolism and evaluation of the HRMS data for stable isotopelabeled reporter ions (Table 1) . While insulin and CRH were found to be comparably stable against metabolism by skin tissue microsomes, synacthen was significantly degraded to a series of truncated peptides, potentially representing new target peptides for the detection of synacthen administrations.
Sample preparation strategies
The extraction of insulin and its analogs from plasma and urine specimens is currently realized in most instances by immunoaffinity purification assays with subsequent LC-MS detection [23, 25] . The capability of co-extracting human insulin and its main metabolite DesB 30 insulin was shown in former studies [16, 17] . In these studies, also the diagnostic potential of detecting DesB 30 human insulin in plasma samples to uncover the illicit use of recombinant human insulin was discussed. Due to the known epitope of the used monoclonal antibody encompassing position B 10 of human insulin, the co-extraction of DesB 30 insulin was not surprising. The other identified metabolites, although potentially co-extracted also, do not play a major role in this regard because the expected concentrations are most likely far below the expected limit of detection (LOD) of the method and only for the main metabolite DesB 30 the LOD was found to be sufficient. For synacthen, also immunoaffinity-based assays have been established, but the identified metabolites significantly differ from the intact drug, and co-extraction even by means of polyclonal antibodies is unlikely. Therefore, an alternative approach was tested in this study, enabling the extraction of synacthen and its metabolites from blood samples simultaneously as validated previously [26] . Ideally, also other prohibited peptides are included in this sample preparation strategy and analytical method, facilitating multi-target initial testing procedures. A generic solid-phase extraction after protein precipitation using mixed-mode cation-exchange adsorbent was applied to extract the metabolites from blood samples (serum or plasma), allowing for the detection of synacthen metabolites (generated in vitro as described earlier) as demonstrated in Figure 7 . According to the detected signal intensities in the chromatogram, Syn 1-15 represents one of the main metabolites under the chosen conditions. 
Proof of concept
As in-vitro experiments represent simplified metabolism models only, proof-of-concept data from post-administration samples are essential for method development purposes. Therefore, in the present study, a post-administration plasma sample from a diabetic patient regularly treated with recombinant human insulin was tested. The sample was analyzed in accordance to a formerly described protocol [16] . In brief, after protein precipitation, evaporation, and extraction with magnetic beads-based immunoaffinity purification, the sample was analyzed by LC coupled to high-resolution MS. Besides intact human insulin, also the main in-vitro generated metabolite DesB 30 human insulin was detected ( Figure 8 ). It is noteworthy that all other metabolites, which were generated in vitro to a lesser extent, could not be detected in this sample.
Conclusions
In this study, it has been shown that the combination of in-vitro metabolism employing skin tissue microsomes and stable isotope-labeled peptides represents an efficient tool to identify relevant metabolites (degradation products or catabolites) of peptide-based drugs. The IRIS strategy enables the detection of metabolites still bearing the isotopic label in at least one of the amino acid residues by HRMS analysis and facilitates the identification of target peptides for doping controls. Especially for peptidic drugs that are applied subcutaneously, the chosen conditions represent an appropriate model for in-vitro experiments. Nevertheless, for insulin and corticotropin, the degree of metabolic degradation was found to be comparably low, and thus, screening for the intact drug is still advised. For less stable peptides, the approach enabled the detection of a variety of metabolites, which can support prolonging the detection window for prohibited substances after parenteral administration. This was shown in earlier studies for LongR 3 -IGF-I, which is also known to be metabolically instable [18] . Here, the window of detection after administration to rodents was prolonged from approximately 2 h for the intact parent drug to at least 12 h for the studied metabolites [18] . For synacthen, the final proof of concept by analyzing in-vivo samples is still missing and will be one of the crucial future steps. 
